GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (OTCPK:NTBLQ) » Definitions » Earnings Yield (Joel Greenblatt) %

NTBLQ (Notable Labs) Earnings Yield (Joel Greenblatt) % : -243.90% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Earnings Yield (Joel Greenblatt) %?

Notable Labs's Enterprise Value for the quarter that ended in Jun. 2024 was $3.77 Mil. Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-9.22 Mil. Notable Labs's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2024 was -243.90%.

The historical rank and industry rank for Notable Labs's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

NTBLQ' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 400
Current: 400

During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Notable Labs was 400.00%. The lowest was 0.00%. And the median was 0.00%.

NTBLQ's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -12.805 vs NTBLQ: 400.00

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Notable Labs's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Notable Labs Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Notable Labs's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Earnings Yield (Joel Greenblatt) % Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - -200.00

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial - - -200.00 -70.42 -243.90

Competitive Comparison of Notable Labs's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Notable Labs's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Notable Labs's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Notable Labs's Earnings Yield (Joel Greenblatt) % falls into.


;
;

Notable Labs Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Notable Labss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-14.657/7.26802
=-201.66 %

Notable Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.22 Mil.



Notable Labs  (OTCPK:NTBLQ) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Notable Labs Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Notable Labs's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs Business Description

Industry
Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.